ArticleScientific reports2025
A branching bivariate weibull distribution model for evaluating exosomes in androgen-deprived agency in the presence of prostate cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic, predictive, and therapeutic approaches for impacted canines: a systematic review and meta-analysis.BMC oral health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castration-resistant prostate cancer (CRPC) poses a significant challenge in the medical field. The study developed a novel model, the branching bivariate Weibull distribution (BBWD), tailored to address CRPC and stems from the maximum likelihood estimation (MLE) function. It considers a medicinal biosystem aimed at transitioning androgen-dependent prostate cancer into an androgen-independent state. The BBWD model is designed to optimize the solution for bio variables pertinent to CRPC and evaluate various treatment techniques for androgen-dependent and androgen-independent behaviour. Through rigorous analysis, the kinetics of LINC01213 in androgen-deprived mediums are highlighted as promising, showing superior efficacy in castration compared to other techniques. The model utilizes the joint effect on the log-likelihood function (JELF) as a crucial analytical tool to assess the impact of LINC01213 in both normal and androgen-deprived medium. The results affirm the veracity of statements made within the medical field and support the notion that LINC01213 may serve as a novel therapeutic target for CRPC patients. The analysis underscores the pivotal role of exosomal LINC01213 in androgen-dependent prostate cancer, demonstrating its significance in treatment efficacy. The BBWD model highlighting the efficacy of LINC01213 in androgen-deprived mediums provides compelling evidence for its potential as a therapeutic target. This study corroborates existing medical hypotheses and offers detailed clarification and reports on treatment techniques for prostate cancer patients. Ultimately, it emphasizes the critical role of exosomal LINC01213 in addressing the challenges posed by androgen-dependent prostate cancer, offering a pathway toward more effective treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.